Frontlight ResearchEarly access
Haemophilia trials in United States
27 of 43 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleSafety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Where
- Indianapolis, Madison, New York, Philadelphia, Rancho Cordova, Sacramento, San Francisco, Seattle, Tampa
- Age
- 18 years and over
- People
- 173 worldwide
- Run by
- Pfizer
See details and how to joinNCT05568719 - Phase 4Taking peopleNuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
- Where
- Dallas
- Age
- 12 years and over
- People
- 28 worldwide
- Run by
- Octapharma
See details and how to joinNCT05935358 - Phase 4Taking peopleNuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- Where
- San Antonio
- Age
- 12 years and over
- People
- 28 worldwide
- Run by
- Octapharma
See details and how to joinNCT05936580 - Phase 4Taking peopleEfanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- Where
- Columbus, Indianapolis, Iowa City, Los Angeles, Portland, Sacramento, Seattle
- Age
- 12 years and over
- People
- 35 worldwide
- Run by
- Sanofi
See details and how to joinNCT06941870 - Phase 1/2Taking peopleA Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
- Where
- Newark, New Haven, New York, Orange, San Francisco, Vallejo
- Age
- 18 years and over
- People
- 5
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07226206 - Phase 3Taking peopleA Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors
- Where
- Flowood
- Age
- 12 years to 74 years
- People
- 95
- Run by
- Pfizer
See details and how to joinNCT07923981 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
- Where
- Indianapolis, Iowa City, Sacramento, Washington D.C.
- Age
- 2 years to 59 years
- People
- 60 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05987449 · EU 2023-503906-35-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Where
- Ann Arbor, Aurora, Indianapolis, Iowa City, Miami, Minneapolis, Orange, San Antonio, Seattle, Tampa
- Age
- 12 years and over
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00 - Phase 3Taking peopleA Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
- Where
- Burlington, Chapel Hill, Charlottesville, Dallas, Durham, Hershey, Houston, Iowa City, Metairie, Minneapolis, Oklahoma City, Philadelphia, Richmond, Rochester, Salt Lake City, San Antonio, Seattle, St Louis
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07830732 · EU 2026-525529-19-00 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
- Where
- Ann Arbor, Dallas, Hackensack, Las Vegas, Los Angeles, Orange, Torrance
- Age
- 1 year to 11 years
- People
- 85 worldwide
- Run by
- Sanofi
See details and how to joinNCT07285460 · EU 2025-521858-42-00 - Phase 3Taking peopleOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Where
- Iowa City, New Hyde Park, Philadelphia, Seattle
- Age
- 1 year to 74 years
- People
- 245 worldwide
- Run by
- Pfizer
See details and how to joinNCT05145127 · EU 2022-500470-33-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Where
- Aurora, Iowa City
- Age
- 12 years and over
- People
- 138 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416526 · EU 2025-522434-32-00 - Phase 1/2Taking peopleA Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- Where
- Ann Arbor, Aurora, Columbus, Dallas, Gainesville, Houston, Indianapolis, Los Angeles, Nashville, New Haven, New Orleans, Philadelphia, Phoenix, Sacramento, San Francisco
- Age
- 2 years and over
- People
- 130 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06379789 · EU 2023-507260-40-00 - Phase 3Taking peoplePhase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
- Where
- Ann Arbor, Atlanta, Gainesville, Memphis, Orange, San Diego
- Age
- 138 months to 206 months
- People
- 20 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07080905 · EU 2023-505805-18-00 - Phase 1Taking peopleA Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
- Where
- Greenville, La Jolla, Los Angeles, San Diego
- Age
- 12 years to 74 years
- People
- 15 worldwide
- Run by
- Pfizer
See details and how to joinNCT06703606 - Phase 3Taking peopleA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Where
- Salt Lake City
- Age
- 1 year to 17 years
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05611801 · EU 2022-500495-65-00 - Phase 4Taking peopleA Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
- Where
- Flowood, Los Angeles
- Age
- 12 years and over
- People
- 20 worldwide
- Run by
- Sanofi
See details and how to joinNCT06145373 · EU 2022-502414-84-00 - Phase 1Taking peopleA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
- Where
- Aurora, Hershey, Indianapolis, Iowa City, Philadelphia
- Age
- 18 years to 64 years
- People
- 30 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07220564 · EU 2025-520490-38-00 - Phase 3Taking peopleEfficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Where
- Ann Arbor, Houston, Pittsburgh, San Diego
- Age
- 18 years and over
- People
- 35 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06003387 · EU 2023-509590-23-00 - Phase 4Not yet taking people in United StatesUnderstanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction
- Where
- Milwaukee
- Age
- 0 years to 17 years
- People
- 15
- Run by
- Versiti Blood Health
See details and how to joinNCT07158606 - No phaseNot yet taking people in United StatesStudy of a Smart Sharps Disposal Device in Patients With Hemophilia
- Where
- Philadelphia
- Age
- 18 years and over
- People
- 23
- Run by
- University of Pennsylvania
See details and how to joinNCT07421154 - Phase 1Taking peopleA Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Where
- Ann Arbor, Chicago, Glendale, Greenville, Hershey, Los Angeles, Metairie, Philadelphia, St Louis
- Age
- 18 years to 60 years
- People
- 31 worldwide
- Run by
- Equilibra Bioscience LLC
See details and how to joinNCT06349473 - Phase 1Taking peopleEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
- Where
- Ann Arbor, Coral Gables, Hershey, Indianapolis, Kansas City, Madison, Mount Pleasant, Orange, Peoria, Redwood City, Seattle, Tampa
- Age
- 0 years to 90 years
- People
- 40
- Run by
- Bleeding and Clotting Disorders Institute Peoria, Illinois
See details and how to joinNCT05500807 - No phaseEnrolling by invitationPalliative Care Needs of Children With Rare Diseases and Their Families
- Where
- Washington D.C.
- Age
- 12 months to 99 years
- People
- 480
- Run by
- Children's National Research Institute
See details and how to joinNCT06938542 - Phase 4Taking peopleSEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
- Where
- Atlanta, Boston, Cleveland, Detroit, Greenville, Houston, Kansas City, Lansing, Little Rock, Los Angeles, Minneapolis, Nashville, New Hyde Park, Oklahoma City, Orlando, Phoenix, Rochester, Sacramento, Savannah, Washington D.C.
- Age
- 12 years to 100 years
- People
- 55
- Run by
- American Thrombosis and Hemostasis Network
See details and how to joinNCT04647227